Discordance between radiographic endpoints and OS in NSCLC patients treated with anti-PD-1/PD-L1 agents was reported in several studies, suggesting that progression-free survival (PFS) and objective response rate (ORR) based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) do not fully capture the clinical benefit of immunotherapy[11-13]. Here, CD274 is linked to non-small cell lung carcinoma.